Isatuximab
Sarclisa (isatuximab) is an antibody pharmaceutical. Isatuximab was first approved as Sarclisa on 2020-05-30. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. The pharmaceutical is active against ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.
Trade Name |
Sarclisa |
---|---|
Common Name |
isatuximab |
ChEMBL ID |
CHEMBL3545131 |
Indication |
multiple myeloma |
Drug Class |
Monoclonal antibodies: chimeric, tumors as target |
Image (chem structure or protein)

$4,995
Want to know more?
Schedule a demo or contact us for additional purchasing options.
Every Drug Dataset Includes...
Full dataset compatible with-

SQL for web applications

R for statistical modeling

Spotfire & Tableau for visualization

CSV export file format

JSON export file format

XLSX export file format
Continually updated information available as a yearly subscription for individual drug-of-interest.